Furiex up on diabetes approvals

Furiex Pharmaceuticals Inc. (NASDAQ:FURX) jumped $14.10 (66%) to $35.34 on Monday after FDA approved late last Friday three Type II diabetes products from partner Takeda Pharmaceutical Co. Ltd. (Tokyo:4502). The stock move translates to a gain in Furiex's market cap of $141.2 million for a closing valuation of $353.9 million. FDA approved Nesina alogliptin along with the combination products Kazano alogliptin/metformin and Oseni alogliptin/pioglitazone (see BioCentury, Jan. 25). ...